Pre-Open Stock Movers 12/01 (PZR) (VNET) (GRPN) Higher; (DWA) (GDP) (HE) Lower (more...)

December 1, 2014 9:32 AM EST

Paramount Gold And Silver Corp. (NYSE: PZG) 18% HIGHER; Reports from Reuters Coeur Mining (NYSE: CDE) is in talks to acquire the company.

ImmunoCellular Therapeutics, Ltd. (NYSE: IMUC) 15.4% HIGHER; announced that the European Medicines Agency (EMA) has provided scientific advice supportive of advancing ICT-107 to a registrational phase III program in patients with newly diagnosed glioblastoma (GBM). The EMA guidance is consistent with the positive feedback the Company received from the US FDA relative to the scope, design and endpoints of the program and the inclusion of patients based on HLA and MGMT status. ImmunoCellular intends to finalize the design of the phase III program, ensuring harmony between US and EU trial protocols, with the goal of being in position to initiate the phase III program. The Company now is evaluating options for funding the phase III program, which may enable the initiation in 2015.

21Vianet Group (NASDAQ: VNET) 7% HIGHER; announced that affiliates of Kingsoft Corporation Limited, a leading internet based software developer, distributor and service provider, Xiaomi Corporation ("Xiaomi"), a leading designer, manufacturer and marketer of mobile devices and other electronic equipment and a provider of internet services, and Temasek, a Singapore based investment company, have entered into definitive share purchase agreements with 21Vianet. All shares to be issued in these transactions are newly issued shares of 21Vianet.

DreamWorks Animation (NASDAQ: DWA) 7% LOWER; Weak Penguins of Madagascar open. FBR Capital downgraded from Market Perform to Underperform with a price target of $14.00 (from $20.00)

Goodrich Petroleum (NYSE: GDP) 5% LOWER; KeyBanc downgraded from Buy to Hold

Groupon, Inc. (NASDAQ: GRPN) 5% HIGHER; BofA/Merrill Lynch upgraded from Neutral to Buy with a price target of $9.50

Hawaiian Electric (NYSE: HE) 4% LOWER; negative Barron's

Momenta Phama (NASDAQ: MNTA) 3.3% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the investigation of necuparanib, the Company's novel oncology drug candidate, as a first-line treatment in combination with Abraxane® and gemcitabine in patients with metastatic pancreatic cancer. Momenta recently announced the successful completion of Part A of the Phase 1/2 study and has initiated the Part B (Phase 2 proof-of-concept) study.

JetBlue Airways (NASDAQ: JBLU) 2.7% HIGHER; BofA/Merrill Lynch upgraded from Underperform to Buy with a price target of $17.00.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Special Reports

Related Entities

Temasek Holdings, KeyBanc, Barron's, Pre-Open Losers, Pre-Open Winners, Definitive Agreement